CryoPort has entered an agreement to support TiGenix’s Phase Ib/IIa clinical trial to investigate the safety and efficacy of Cx611 to treat sepsis in adults with severe community‐acquired bacterial pneumonia.
Cx611 is a donor-derived stem cell platform that aims to develop a new treatment for sepsis.
Under the latest agreement, Cryoport will provide global logistics support for transporting cryogenically preserved clinical commodities to TiGenix.
Using Cryoport solutions, TiGenix will be able to constantly monitor its shipments and track the conditions and location of its stem cells while in transit.
The arrangement is also expected to smoothly conduct TiGenix’s new randomised double-blind placebo-controlled SEPCELL trial that expects to enrol 180 patients at up to 50 centres.
Cryoport CEO Jerrell Shelton said: “Sepsis is a potentially life-threatening complication of infection, which can lead to systemic inflammation and, in the worst cases, organ failure.
“The emergence of increasingly drug-resistant bacteria, alongside ageing populations around the world, is driving a growing number of sepsis cases.
“TiGenix aims to leverage the anti-inflammatory properties found in stem cells to develop a novel treatment for sepsis, using its allogeneic (donor derived) stem cell platform, Cx611.”
Currently, Cryoport provides its solutions to points-of-care, central laboratories, pharmaceutical companies, manufacturers, university researchers, and others.
The company’s current range of temperature controlled logistics solutions includes Cryoport Express shippers, SmartPak II condition monitoring system, Cryoportal logistics management platform, among others.